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Cyclin F, a cyclin that can form SCF complexes and
bind to cyclin B, oscillates in the cell cycle with a pat-
tern similar to cyclin A and cyclin B. Ectopic expression
of cyclin F arrests the cell cycle in G2/M. How the level of
cyclin F is regulated during the cell cycle is completely
obscure. Here we show that, similar to cyclin A, cyclin F
is degraded when the spindle assembly checkpoint is
activated and accumulates when the DNA damage
checkpoint is activated. Cyclin F is a very unstable pro-
tein throughout much of the cell cycle. Unlike other
cyclins, degradation of cyclin F is independent of ubiq-
uitination and proteasome-mediated pathways. Inter-
estingly, proteolysis of cyclin F is likely to involve metal-
loproteases. Rapid destruction of cyclin F does not re-
quire the N-terminal F-box motif but requires the
COOH-terminal PEST sequences. The PEST region
alone is sufficient to interfere with the degradation of
cyclin F and confer instability when fused to cyclin A.
These data show that although cyclin F is degraded at
similar time as the mitotic cyclins, the underlying mech-
anisms are entirely distinct.
Cyclins and cyclin-dependent kinases (CDKs)1 are key reg-
ulators of the eukaryotic cell cycle. In mammalian cells, differ-
ent cyclin-CDK complexes are involved in regulating different
cell cycle transitions: cyclin D-CDK4/6 for G1 progression, cy-
clin E-CDK2 for the G1-S transition, cyclin A-CDK2 for S phase
progression, and cyclin A/B-CDC2 for entry into M phase (1).
Apart from these well known roles in the cell cycle, several
cyclins and CDKs are involved in processes not directly related
to the cell cycle. Cyclin D can bind and activate the estrogen
receptor, and CDK5 is activated in postmitotic neurons by p35.
The cyclin H-CDK7 complex is a component of both the CDK-
activating kinase and the basal transcription factor TFIIH and
can phosphorylate CDKs and the carboxyl-terminal repeat do-
main of the large subunit of RNA polymerase II, respectively.
Other cyclins and CDKs (cyclin C-CDK8, cyclin T-CDK9, and
cyclin K) are also known to associate with RNA polymerase II
and phosphorylate the carboxyl-terminal repeat domain. Cy-
clin G, a target of p53, recruits PP2A to dephosphorylate
MDM2 (2). Finally, cyclin T-CDK9 interacts directly with the
human immunodeficiency virus type-1 Tat protein and en-
hances Tat binding to the viral TAR RNA stem-loop structure.
Despite the large amount of information known about cyc-
lins, the functions and regulation of several “orphan” cyclins,
notably cyclin F and cyclin I, remain to be determined. Cyclin
F is the largest and in many respects one of the most interest-
ing members of the cyclin family. Apart from the cyclin box
region common to all cyclins, cyclin F also contains an F-box
motif at the N terminus and PEST sequences at the COOH-
terminal quarter of the protein. The F-box motif (which origi-
nally derived its name from cyclin F) is responsible for binding
to SKP1 in the formation of the SCF ubiquitin ligase complex
(3). The PEST sequence (proline-, glutamic acid-, serine-, and
threonine-rich) is typically present in rapidly turnover proteins
(4). Finally, the cyclin box of cyclin F is highly unusual, because
no CDK partners have been identified, and it can bind to
another molecule of cyclin (5).
The expression profile of cyclin F is most similar to that of
cyclin A. Cyclin F mRNA begins to accumulate in S phase,
peaks in G2, and declines before mitosis. The accumulation and
decline of cyclin F mRNA occur slightly ahead of cyclin B1 and
nearly coincide with the profile of cyclin A mRNA (6). Accumu-
lation of cyclin A and cyclin F mRNA during G2 phase has been
confirmed by microarray analysis (7). At the protein level,
cyclin F accumulates during S phase and decreases around
mitosis, again similar to cyclin A (6, 8).
Overexpression of cyclin F causes an accumulation of the
G2/M population (6). This effect is stronger with a mutant
cyclin F lacking the PEST region. However, it is not clear
whether this is due to a delay of G2/M, a shortening of G1 or S,
or the competition with a common CDK partner. Overex-
pressed cyclin F accumulates in the nucleus due to the presence
of two nuclear localization sequences, but a portion of cells also
displays perinuclear staining (5, 6). In this connection, it has
been shown that the cyclin box region of cyclin F can bind to the
cytoplasmic retention sequence region of cyclin B1 by yeast
two-hybrid, in vitro binding, and co-immunoprecipitation as-
says (5). It is believed that during the G2/M transition, cyclin F
may carry cyclin B1 (which lacks its own nuclear localization
sequence) into the nucleus by virtue of the nuclear localization
sequence in cyclin F.
Ubiquitin/proteasome-dependent proteolysis of cyclin A and
cyclin B requires a short sequence near their N terminus called
the destruction box (D-box) (9, 10). The ubiquitin ligase E3 for
cyclin B1 in mitosis is the anaphase-promoting complex/cyclo-
some complexed with CDC20 (11). Cyclin A is probably also
degraded by anaphase-promoting complex/cyclosome-CDC20
(12–15), although the difference in the timing of degradation
between cyclin A and cyclin B1 argues for the involvement of
distinct mechanisms.
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Despite the fact that cyclin A and cyclin F are degraded at
the same time, no D-box sequence is recognized in cyclin F.
Instead, PEST sequences at the COOH-terminal quarter of
cyclin F may represent a possible destruction signal (4). It is
noteworthy that other mammalian cyclins including cyclin
D1, cyclin T1, and cyclin G2 also contain PEST sequences.
The molecular basis of proteolysis of PEST-containing pro-
tein is far from clear. Proteolysis of several PEST-containing
proteins involves the Ca2-dependent protease calpain (16,
17), whereas proteolysis of other PEST-containing proteins
by calpain is shown to be independent of the PEST sequences
(18, 19).
Another major class of ubiquitin ligase is the SCF complex
comprising SKP1, CUL1, and F-box proteins (20). The F-box
motif (first found in cyclin F, Cdc4p, and Skp2p) is involved in
direct interaction with SKP1 (3). It is believed that SCF com-
plexes composed of different F-box subunits target different
substrates for ubiquitination. Examples of SCF functions in-
clude the ubiquitination of cyclin E by SCFCDC4 and SCFFBW7
(21, 22) and p27KIP1 by SCFSKP2 (22–24). Although cyclin F is
one of the founding members of the F-box protein family, it is
still unclear whether cyclin F can function as an ubiquitin
ligase. Furthermore, little is known about how the variation
of cyclin F is controlled in the cell cycle and how it is related
to cyclin A and cyclin B. Several F-box proteins including
Cdc4p (25–27) and SKP2 (28, 29) are themselves degraded by
the ubiquitin/proteasome system, but it is unclear whether
the same pathway also degrades cyclin F.
EXPERIMENTAL PROCEDURES
Materials—All reagents were from Sigma unless stated otherwise.
DNA Constructs—Cyclins in this study were of human origin, and
the subtypes were cyclin A2, cyclin B1, and cyclin E1. Cyclin F in
pET11d, FLAG-cyclin F in pUHD-P1, FLAG-cyclin A in pUHD-P1, and
cyclin E in pLINX were as described previously (30). Cyclin F lacking
the N-terminal F-box region (N79) or cyclin F with only the PEST
region (N565) were constructed by PCR using the primers T7 termi-
nator and 5-TGCCATGGTCCAGGAGCTGTGGCCGTC-3 (for N79)
or 5-TCCCATGGGGCGGAGAACCAAAC-3 (for N565) from cyclin F
in pET11d; the NcoI-EcoRI fragments were then put into pUHD-P1 or
pET21d. Cyclin F in pET11d cut with AvaI was used directly in in vitro
translation to produce cyclin F lacking the COOH-terminal PEST re-
gion (C565). FLAG-cyclin A-cyclin F(N565) (cyclin A fused to the
PEST region of cyclin F) was created by putting the NcoI-cut fragment
of cyclin A generated from PCR into FLAG-cyclin F(N565) in pUHD-
P1. FLAG-SKP2 for mammalian expression and cyclin A and cyclin
A(N71) (D-box) for reticulocyte lysate expression were as described
previously (31). Human ubiquitin cDNA was a gift from Dr. Tim Hunt
(Cancer Research UK). Ubiquitin (Ub) was amplified by PCR with
primers 5-TCCCATGGAAATCTTTGTAAAA-3 (ubiquitin forward
primer introducing an NcoI site) and 5-GGGCCATGGCTAGTTATT-
GCTCAGCGGTGG-3 (T7 terminator primer introducing an NcoI site),
cut with NcoI, and ligated into pUHD-P2 (30) to produce hemagglutinin
(HA)-Ub in pUHD-P2.
Cell Culture—HtTA1 cells are HeLa cells (human cervical carci-
noma) expressing the tTA tetracycline repressor chimera (30). Cells
FIG. 1. Cyclin F is accumulated and destroyed at similar time as cyclin A and is not stabilized by nocodazole. A, anti-cyclin F
antibodies. Cell-free extracts (200 g) were immunoprecipitated with normal rabbit serum (lane 2) or antiserum raised against SKP2 (lane 1) and
cyclin F (lane 3). One-third of the immunoprecipitates and 10 g of total cell lysates (lane 4) were loaded onto SDS-PAGE and immunoblotted with
antibodies against cyclin F. B, cells were synchronously released from early S phase with a double thymidine block method as described under
“Experimental Procedures.” The cells were prevented to progress through the subsequent mitosis with nocodazole. Cell extracts were prepared at
the indicated time points and cyclin B, cyclin A, cyclin F, and CDC2 were detected by immunoblotting. C, a portion of cells from the synchronization
experiment shown in B were stained with propidium iodide and analyzed with flow cytometry. The positions of 2 and 4 N DNA content are
indicated.
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were blocked at mitosis by incubation in medium containing 0.1 g/ml
nocodazole for 16 h. Cells in G1 phase were obtained 3 h after released
from nocodazole block. Cells were blocked in S phase by incubation in
medium containing 1.5 mM hydroxyurea for 24 h. In promoter turn-off
experiments, doxycycline (1 g/ml) was added to the medium at 24 h
after transfection, and the cells were harvested at the indicated time. In
some experiments, cells were treated with actinomycin D (100 ng/ml),
cycloheximide (10 g/ml), LLnL (also called MG101) (50 M), and LLM
(50 M) for the indicated time.
Synchronization and Flow Cytometry—Cells were synchronized with
a double thymidine method as described previously (8). Nocodazole (0.1
mg/ml) was added when the cells were released from the second block to
prevent them from progressing through the subsequent mitosis. Flow
cytometry after propidium iodide staining was performed as described
previously (32).
Expression of Recombinant Proteins—Transient transfection and
preparation of cell-free extracts were performed as described previously
(30). Coupled transcription-translation reactions in the presence of
[35S]methionine in rabbit reticulocyte lysate were performed according
to the manufacturer’s instructions (Promega, Madison, WI).
Degradation and Ubiquitination Assays—For in vitro protein degra-
dation assays, reticulocyte lysate programmed to express recombinant
proteins in the presence of [35S]methionine (1 l) was mixed with 9 l
of buffer or synchronized cell extracts. The reactions were supple-
mented with an energy regeneration system (25 mM phosphocreatine,
10 mg/ml creatine kinase, and 1 mM ATP). Unless stated otherwise, the
reactions were incubated at 30 °C for 90 min and stopped with SDS-
sample buffer and boiling. For in vivo ubiquitination assays, constructs
expressing FLAG-tagged proteins were co-transfected with HA-Ub in
pUHD-P2. The cells were treated with 50 M of LLnL for 6 h before they
were harvested. Cell extracts prepared from the transfected cells were
immunoprecipitated with either normal rabbit serum or rabbit anti-
FLAG polyclonal antibodies. The presence of HA-Ub-conjugated pro-
teins in the immunoprecipitates was detected by immunoblotting with
the anti-HA monoclonal antibody 12CA5.
Antibodies and Immunological Methods—Immunoblotting and im-
munoprecipitation were performed as described previously (33). Rat
monoclonal antibodies YL1/2 against mammalian tubulin, monoclonal
antibody HE12 against cyclin E1, monoclonal antibody E23 against
cyclin A2 (31), monoclonal antibody A17 against CDC2 (34), anti-
PSTAIRE monoclonal antibody (35), and rabbit anti-FLAG polyclonal
antibodies (30) were obtained from sources as described previously.
Monoclonal antibody GNS1 against cyclin B1 (sc-245), rabbit anti-cyclin
F polyclonal antibodies (sc-952), goat anti-SKP1 antibodies (sc-1568),
and goat anti-SKP2 antibodies (sc-1567) were from Santa Cruz Biotech-
nology (Santa Cruz, CA). Monoclonal antibody M2 against FLAG tag
was obtained from Sigma, and monoclonal antibody 12CA5 against HA
tag was from Roche Molecular Biochemicals.
RESULTS
Cyclin F Is Destroyed at a Similar Time as Cyclin A but Is
Not Affected by Replication and Spindle Checkpoints—We first
confirmed that the antibodies that we used recognize endoge-
nous cyclin F. Total HeLa cell extracts and cyclin F immuno-
FIG. 2. Cyclin F is destroyed in nocodazole-treated cells by
proteasome-independent mechanisms. A, accumulation of A-, B-,
and E-type cyclins but not cyclin F in hydroxyurea-treated cells. HeLa
cells were either mock-treated or were blocked in S phase with hy-
droxyurea as described under “Experimental Procedures.” Cell-free ex-
tracts were prepared, and cyclin F, cyclin A, cyclin B, and cyclin E were
detected by immunoblotting. B, accumulation of cyclin B and loss of
cyclin A, cyclin E, and cyclin F in nocodazole-treated cells. HeLa cells
were either mock-treated (lanes 1 and 3) or blocked in metaphase with
nocodazole as described under “Experimental Procedures.” Proteasome
inhibitor LLnL was added 6 h before the cells were harvested. Cell-free
extracts were prepared and cyclin B, cyclin A, cyclin E, and cyclin F
were detected by immunoblotting. Tubulin and SCF components (SKP1
and SKP2) were also analyzed in the same samples.
FIG. 3. Cyclin F increases after DNA damage. A, DNA damage-induced cell cycle arrest. Cells were treated with buffer, ADR (0.07 g/ml),
or CMP (0.7 M) for 24 h. The cells were processed for flow cytometry analysis as described under “Experimental Procedures.” B, increase of cyclin
F after DNA damage. Cells were treated with buffer (lane 1) or increasing dosage of ADR (3-fold serial increase from 7 ng/ml in lane 2 to 0.6 g/ml
in lane 6) and CMP (3-fold serial increase from 0.07 M in lane 7 to 6 M in lane 11) for 24 h. Cell extracts were prepared and CDC2, cyclin B, cyclin
A, and cyclin F were detected by immunoblotting. The asterisk indicates the slower migrating, phosphorylated form of CDC2.
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precipitates were subjected to immunoblotting. Fig. 1A shows
that 100-kDa proteins were detected in total extracts and in
cyclin F immunoprecipitates but not in immunoprecipitates
using normal rabbit serum or serum against SKP2 (another
F-box protein). The bands recognized by the antibodies co-
migrated with recombinant cyclin F (data not shown).
We next looked at the oscillation of cyclin F during G2 phase
in relation to other mitotic cyclins and to see whether cyclin F
is affected by checkpoints. HeLa cells were first blocked in early
S phase with a double thymidine block method and then syn-
chronously released. We trapped the cells in the subsequent
mitosis with nocodazole. As expected, cyclin A was destroyed
during G2 phase, and cyclin B was stabilized during the no-
codazole-induced spindle assembly checkpoint (Fig. 1B). Flow
cytometry indicated that these cells were synchronously re-
leased from the early S phase trap and reached G2 phase by 6 h
(Fig. 1C). In comparison with cyclin A, cyclin F was synthesized
and destroyed more abruptly. Similar to cyclin A but unlike
cyclin B, cyclin F was not stabilized by the spindle checkpoint.
The relatively constant level of CDC2 served as gel loading
control.
Given that both cyclin A and cyclin B accumulated when cells
were blocked in S phase, we next examined whether cyclin F
was affected by the DNA replication checkpoint. Fig. 2A shows
that the levels of cyclin A, cyclin B, and cyclin E were higher in
hydroxyurea-treated cells than in control cells. In contrast,
similar level of cyclin F was present in these samples, indicat-
ing that cyclin F was not stabilized by the DNA replication
checkpoint.
Cyclin F Is Degraded through Proteasome-independent
Mechanisms—To see whether the degradation of cyclin F in-
volves proteasomes, cells were treated with nocodazole in the
presence or absence of the proteasome/calpain inhibitor LLnL.
As expected, cyclin A, cyclin E, and cyclin F were destroyed
after nocodazole treatment, but cyclin B was stabilized (Fig.
2B, lane 2). The destruction of cyclin A and cyclin E requires
the proteasome and was abolished by the presence of LLnL
(lane 4). In marked contrast, cyclin F was still destroyed in the
presence of nocodazole and LLnL. The relatively constant level
of tubulin acted as controls for sample loadings. For compari-
son, the levels of SKP1 (a protein that binds to the F-box region
of cyclin F) and SKP2 were not affected by nocodazole and/or
LLnL.
Accumulation of Cyclin F during G2 and S DNA Damage
Checkpoints—Adriamycin (ADR) and camptothecin (CMP) are
inhibitors of topoisomerase II and topoisomerase I, respec-
tively. Both reagents eventually induce double-stranded
breaks in the DNA, but the action of CMP appears to be limited
to S phase (reviewed in Ref. 36). ADR-arrested HeLa cells in G2
phase and CMP-arrested cells predominantly in S phase (Fig.
3A). CDC2 shifted to a slower migrating form that represented
Thr14/Tyr15 phosphorylation and inactivation of its kinase ac-
tivity (Fig. 3B). Furthermore, both cyclin A and cyclin B accu-
mulated after ADR and CMP treatments. The levels of cyclin A
and cyclin B declined at higher dosage of ADR and CMP,
probably due to cell death at these levels of DNA damage.
Interestingly, cyclin F also accumulated after ADR or CMP
treatments, mirroring closely the inactivation of CDC2.
FIG. 4. Endogenous cyclin F is unstable. Asynchronous growing (A) or S phase-arrested (B) cells were treated with actinomycin D (Act D),
cycloheximide (CHX), or both reagents together. Cell extracts were prepared at the indicated time points and were subjected to immunoblotting
with antibodies against cyclin F, cyclin A, cyclin B, and CDC2.
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Taken together, these data showed that the important check-
points that affect cells from S phase to mitosis have different
effects on different cyclins. The A-, B-, and E-type cyclins are
stabilized by the DNA replication checkpoint. In contrast, only
cyclin B is stabilized by the spindle assembly checkpoint.
Finally, the A-, B-, and F-type cyclins accumulated during the
DNA damage checkpoints that delay S phase and G2 phase.
Cyclin F Is an Unstable Protein in Vivo—We next analyzed
the stability of the endogenous cyclin F in relation to other
cyclins. When de novo protein synthesis was inhibited with
cycloheximide, cyclin F disappeared in less than 1 h (Fig. 4A,
lanes 6–10), suggesting that cyclin F was a very unstable
protein in growing cells. Cyclin F also decreased when tran-
scription was blocked with actinomycin D, but this occurred
more slowly than with cycloheximide (lanes 1–5). This indicates
that cyclin F protein has a shorter half-life than its mRNA. Not
surprisingly, adding actinomycin D and cycloheximide together
induced the disappearance of cyclin F at similar rate as with
cycloheximide alone. In contrast, cyclin A and cyclin B were
more stable than cyclin F, and reduction of the proteins were
only appreciable at later time points. The relatively stable
protein CDC2 acted as a control for sample loading.
Since cyclin F starts to accumulate during S phase, we next
investigated the stability of cyclin F in the presence of hy-
droxyurea (Fig. 4B). A similar short half-life of cyclin F protein
was observed in S phase as in growing cells. However, the
mRNA of cyclin F appeared to be more stable during S phase,
since cyclin F remained elevated following actinomycin D treat-
ment. We have not been able to examine the stability of cyclin
F in G2 phase due to the lack of a good nontoxic G2 cell cycle
blocker. Hence, given the short half-life of the protein, the
major determinants of cyclin F level are probably due to tran-
scription control and mRNA stability.
The Stability of Cyclin F Is Not Affected by Other Cyclins—It
is hypothesized that the stability of one cyclin may be affected
by the expression of another type of cyclin. This could be at-
tributed to either a direct effect of the cyclin on the degradation
machinery, or indirectly due to the cell cycle block imposed by
the cyclin. We investigated the stability of cyclin F by putting
its cDNA under the control of a doxycycline-responding pro-
moter. The addition of doxycycline reduced the level of FLAG-
tagged cyclin F to an undetectable level (Fig. 5A). We found
that co-transfection of FLAG-cyclin F with constitutive expres-
sion plasmids for cyclin A, cyclin B, or cyclin E (also shown by
immunoblotting) did not affect the stability of cyclin F. For
comparison, similar experiments performed with cyclin E
showed that its stability was reduced when co-expressed with
cyclin A or cyclin B but not with cyclin F (Fig. 5B). One impli-
cation from these results is that the stability of cyclin F is not
sensitive to cell cycle arrest caused by overexpression of other
cyclins.
Rapid Degradation of Cyclin F Requires the COOH-terminal
PEST Sequence but Not the N-terminal F-box—Cyclin F con-
tains two structural elements that are generally connected to
proteolysis: an F-box motif at the N terminus and the PEST
sequences at the COOH-terminal quarter of the protein. We
used an in vitro degradation system to elucidate the relation-
ship between these structural elements and cyclin F stability.
FIG. 5. The stability of cyclin F is not affected by other cyclins. A, the stability of cyclin F is not affected by co-transfection with other
cyclins. Control vector or plasmids expressing cyclin A, cyclin B, or cyclin E were co-transfected with FLAG-cyclin F in pUHD-P1 as indicated. At
24 h after transfection, doxycycline (Dox) was added to turn off the promoter expressing FLAG-cyclin F. At the indicated time points after the
addition of Dox, cell extracts were prepared and immunoblotted with antibodies against FLAG (for cyclin F) and other cyclins. B, the stability of
cyclin E is reduced in the presence of cyclin A and cyclin B but not by cyclin F. Control vector or plasmids expressing cyclin A, cyclin B, or cyclin
F were co-transfected with cyclin E in pLINX as indicated. At 24 h after transfection, doxycycline was added to turn off the promoter expressing
cyclin E. At the indicated time points after the addition of Dox, cell extracts were prepared, and cyclin E was detected by immunoblotting.
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Radiolabeled cyclin A or cyclin F was produced in a coupled
transcription-translation reticulocyte lysate system. Recombi-
nant cyclin A was destroyed when it was mixed with extracts
from nocodazole-blocked cells (Fig. 6A). Deletion of the N-ter-
minal region of cyclin A that contains the destruction box
sequence (D-box) (see Fig. 6B) abolished its degradation, sug-
gesting that the degradation was not due to nonspecific
proteolysis.
Fig. 6C shows that cyclin F was also degraded using the
same in vitro system. Moreover, degradation of cyclin F was not
affected by removing the F-box region (F-box). Importantly,
the stability of cyclin F was substantially increased when
the PEST-containing COOH-terminal region was removed
(PEST).
We found that whereas cyclin A was degraded by mitotic
extracts, it was relatively stable in G1 cell extracts (Fig. 6D). In
contrast, cyclin F was similarly degraded in both mitotic and
G1 cell extracts. Immunoblotting of the extracts for cyclin B
and PSTAIRE confirmed that the G1 cells had exited mitosis
and that similar amounts of extracts were used, respectively.
These data indicate that whereas the destruction machinery
for cyclin A was active during mitosis but not in G1, the mech-
anism that degraded cyclin F was equally active during mitosis
and G1, further testifying to the difference between the degra-
dation of cyclin A and cyclin F.
To confirm that deletion of the F-box region did indeed dis-
rupt the interaction between cyclin F and SKP1, we looked at
whether recombinant cyclin F could bind to SKP1. Fig. 7A
shows that endogenous SKP1 was co-immunoprecipitated with
FLAG-cyclin F but not with immunoprecipitates of control nor-
mal rabbit serum. For comparison, SKP1 was also co-immuno-
precipitated with SKP2. It is known that SKP2 can form a
complex with cyclin A-CDK complexes (37), as was confirmed
in Fig. 7A. Interestingly, no interaction between cyclin F and
cyclin A-CDK complexes was detected under similar condi-
tions. Significantly, cyclin F lacking the N terminus (F-box)
did not form a complex with SKP1 (Fig. 7B).
Cyclin F Is Not Ubiquitinated in Vivo—We used an in vivo
ubiquitination assay to see whether cyclin F was ubiquitinated.
FLAG-tagged cyclins were co-expressed with a HA-tagged
ubiquitin (HA-Ub), and proteasome inhibitors were added to
stabilize the ubiquitinated proteins. A smear of high molecular
weight, HA-containing proteins in the FLAG immunoprecipi-
tates indicated conjugation of HA-Ub to the cyclins (Fig. 8). As
expected, both cyclin A and cyclin B were ubiquitinated in vivo.
In contrast, no HA-Ub-conjugated protein was seen with
FLAG-cyclin F. As controls, neither FLAG-tagged cyclins nor
HA-Ub-conjugated proteins was immunoprecipitated with nor-
mal rabbit serum. Based on this and other evidence shown
above, we interpret that in contrast to other cyclins, cyclin F
was not targeted by the ubiquitin/proteasome system.
The PEST Sequence of Cyclin F Is Sufficient to Confer Insta-
bility When Transferred to Cyclin A—Given that cyclin F was
not degraded through the ubiquitin/proteasome pathway, what
are the proteases that are responsible for the rapid turnover of
cyclin F? To begin to address this question, inhibitors of various
classes of proteases were added to the in vitro degradation
assay for cyclin F. Fig. 9A shows that the only reagents that
significantly inhibited the degradation of cyclin F were EDTA
and EGTA.
The above datum suggests that degradation of cyclin F may
involve proteases that use metal ions as active centers (metal-
loproteases) or other metal-dependent proteases like calpain. It
is known that proteolysis of several PEST-containing proteins
like IB and c involves calpain (16, 17). Although degradation
of cyclin F was inhibited by EGTA, we do not favor the idea that
calpain is responsible for the rapid turnover of cyclin F. This is
because the cysteine protease inhibitor E64 did not inhibit the
FIG. 6. In vitro degradation of cyclin A and cyclin F. A, in vitro cyclin degradation assays. In vitro translated cyclin A or cyclin A(N71)
was incubated with nocodazole-blocked HeLa cell extracts as described under “Experimental Procedures.” Cyclin A was also incubated with buffer
as controls (lanes 5–7). At the indicated time points, samples were taken for SDS-PAGE, and radiolabeled proteins were detected with
phosphorimaging. B, schematic diagram of the cyclin F and cyclin A constructs used in this study. The positions of the various structural elements
are shown to scale. C, rapid degradation of cyclin F in vitro depends on the PEST but not the F-box region. In vitro degradation assays were
preformed with radiolabeled full-length cyclin F, F-box deletion mutant (F-box), or PEST region deletion mutant (PEST) in nocodazole-blocked
HeLa cell extracts as described under “Experimental Procedures.” The signals were quantified with a PhosphorImager and plotted on the right.
D, cyclin F is degraded with similar efficiency in mitotic and G1 cell extracts. Cyclin A and cyclin F produced in rabbit reticulocyte lysates were
mixed with extracts prepared from cells in mitosis (lane 1) or G1 phase (lane 2). The relative amount of cyclin A and cyclin F after 60 min of
incubation was detected by SDS-PAGE and phosphorimaging. Quantifications of cyclin A and cyclin F are shown on the right (gray, mitosis; black,
G1). The endogenous cyclin B and CDC2/CDK2 were detected by immunoblotting.
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degradation of cyclin F (Fig. 9A). Moreover, the addition of the
specific calpain inhibitor LLM did not stabilize cyclin F in vivo
(Fig. 9B). The addition of the calpain/proteasome inhibitor
LLnL slightly stabilized cyclin F (Figs. 2B and 9B), but LLnL
clearly could not inhibit the degradation of cyclin F in the
presence of nocodazole (Fig. 2B). Taken together, it is possible
that degradation of cyclin F may involve metalloproteases.
To see whether the PEST region of cyclin F was sufficient to
act as an independent unit that influences protein stability, we
subcloned the PEST region alone into a mammalian expression
plasmid and investigated whether it could affect the turnover
of cyclin F. When FLAG-tagged PEST was co-expressed with
cyclin F (with FLAG-PEST in excess), the stability of cyclin F
was higher than when it was expressed alone (Fig. 9C). This
suggests that the excess PEST could interfere with the degra-
dation of full-length cyclin F, possibly through competition
with the endogenous proteases. One caveat to this experiment
is that the half-life of recombinant cyclin F was higher than
that of the endogenous cyclin F. This is probably because cyclin
F produced in these transient transfections was substantially
more abundant than the endogenous protein; hence, expression
of cyclin F itself may already be straining the proteolytic
system.
We next investigated whether the PEST region could confer
instability when transferred to another protein. Cyclin A,
which was relatively stable outside M phase (Fig. 4), was fused
to the PEST region of cyclin F (cyclin A-PEST). We found that
the fusion protein was substantially less stable than cyclin A
(Fig. 9D). Taken together, these data show that the PEST
region of cyclin F is sufficient to decrease the stability of het-
erogeneous protein.
DISCUSSION
Cell Cycle Control of Cyclin F—Among the three cyclins that
are synthesized and destroyed during G2 and mitosis (cyclin A,
cyclin B, and cyclin F), the function and control of cyclin F is the
most elusive. Cyclin B-CDC2 is the classic M phase-promoting
factor that drives entry into mitosis. Cyclin A can activate both
CDC2 and CDK2 and functions in S phase and mitosis (38).
Despite the fact that the cyclin box of cyclin F is most similar to
cyclin A, no CDK partner has been identified for cyclin F. The
one function proposed for cyclin F is its ability to bind cyclin B
and transport it into the nucleus (5).
The synthesis and destruction of cyclin F are typically more
abrupt than for cyclin A and cyclin B. We observed that cyclin
F was consistently destroyed slightly later than cyclin A in
HeLa cells. This was observed when cells were synchronously
released from S phase into a mitotic block (Fig. 1) or when cells
were allowed to progress through mitosis (data not shown). The
tight temporal regulation of cyclin F points to a potentially
important role in the cell cycle.
Both synthesis and destruction of cyclins are important for
cell cycle progression. It is well known that destruction of cyclin
B by anaphase-promoting complex/cyclosome is essential for
metaphase-anaphase transition, and expression of a inde-
structible cyclin B traps cells in mitosis. Similarly, expression
of indestructible cyclin A arrests cells in late mitosis (14, 39).
Overexpression of cyclin F (or mutant lacking PEST) also
FIG. 7. Cyclin F lacking the F-box region cannot bind SKP1. A,
cells were transfected with plasmids expressing FLAG-cyclin F (lane 2),
FLAG-SKP2 (lane 4), or control vectors (lanes 3 and 5). Cell extracts
were then prepared, and 200 g were immunoprecipitated with anti-
FLAG tag serum. Samples were applied onto SDS-PAGE and immuno-
blotted with antibodies against FLAG, SKP2, SKP1, PSTAIRE (which
detected both CDC2 and CDK2), and cyclin A as indicated. Total HeLa
cell extracts (10 g) were loaded in lanes 1 and 6. B, cells were trans-
fected with plasmids expressing FLAG-cyclin F(F-box). Cell extracts
were prepared, and 200 g were immunoprecipitated with normal
rabbit serum (lane 2) or anti-FLAG serum (lane 3). Samples were
applied onto SDS-PAGE and immunoblotted with antibodies against
FLAG and SKP1.
FIG. 8. Cyclin F is not ubiquitinated in vivo. HA-tagged Ub was
co-expressed with FLAG-tagged cyclin B (lanes 1–3), cyclin A (lanes
4–6), or cyclin F (lanes 7–9). Cell extracts were prepared and immuno-
precipitated with either normal rabbit serum (lanes 2, 5, and 8) or
anti-FLAG serum (lanes 3, 6, and 9). Total cell extracts were loaded in
lanes 1, 4, and 7. The samples were subjected to immunoblotting with
antibodies against HA (upper panel) and FLAG (lower panel).
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causes an accumulation of the G2/M population (6), but it is not
known whether the cells are delayed at any particular point
during mitosis. Why is destruction of cyclin F important for
G2/M? Since the nuclear envelope is broken down following the
activation of cyclin B-CDC2 complexes, cyclin F is no longer
required for cyclin B transport after its activation. This sug-
gests that cyclin F has functions in addition to transporting
cyclin B into the nucleus. Another possibility is that the pres-
ence of cyclin F-cyclin B complexes during mitosis could inter-
fere with the normal functions of cyclin B.
Activation of the spindle assembly checkpoint, which delays
metaphase-anaphase transition until all chromosomes are at-
tached to the mitotic spindles, inhibits cyclin B but not cyclin A
degradation (14, 39). We found that, similar to cyclin A, cyclin
F was not stabilized by the spindle assembly checkpoint. Ec-
topic expression of cyclin F did not affect the ability of the cell
to activate the spindle assembly checkpoint.2
As with cyclin A, cyclin F also accumulated slightly after
DNA damage. This was not merely due to an increase of cells in
G2 phase, since camptothecin mainly arrested cells in S phase.
We have not directly determined the stability of cyclin F fol-
lowing DNA damage because of the substantial cell death in-
duced by the DNA-damaging agents and cycloheximide to-
gether. In the case of cyclin A, increase in the protein appears
to be important for DNA damage checkpoints in some cells.
Drosophila cells lacking cyclin A are unable to delay in mitosis
after DNA damage, and they enter anaphase with an increased
2 T. K. Fung, W. Y. Siu, C. H. Yam, A. Lau, and R. Y. C. Poon,
unpublished data.
FIG. 9. Characterization of the PEST sequences of cyclin F. A, degradation of cyclin F in vitro is inhibited by EDTA and EGTA. In vitro
translated cyclin F was mixed with nocodazole-blocked cell extracts as described under “Experimental Procedures.” The reactions were supple-
mented with control buffer, benzamidine (100 g/ml), SBTI (50 g/ml), E64 (10 M), pepstatin (1 M), aprotinin (2 g/ml), EDTA (10 mM), EGTA
(10 mM), phenylmethylsulfonyl fluoride (1 mM), leupeptin (100 M) as indicated. The input and the cyclin F remained after the incubation were
analyzed by SDS-PAGE and phosphorimaging. B, buffer, LLM, or LLnL was added to growing HeLa cells as indicated. Cell extracts were prepared
after 6 h, and the relative level of cyclin F was detected by immunoblotting. C, FLAG-cyclin F was co-transfected with FLAG-PEST (lanes 1–4) or
control vector (lanes 5–8). Cycloheximide was added to inhibit protein synthesis at 24 h after transfection. At the indicated time points after
cycloheximide addition, cell extracts were prepared and the FLAG-tagged proteins were detected by immunoblotting. The signals were quantified
with the NIH Image program and plotted on the right. D, cells were transfected with plasmids expressing FLAG-cyclin A or FLAG-cyclin A-PEST.
Cycloheximide was added to inhibit protein synthesis at 24 h after transfection. At the indicated time points after cycloheximide addition, cell
extracts were prepared, and FLAG-tagged proteins were detected by immunoblotting.
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number of lagging chromosomes (40). The potential role of
cyclin F after DNA damage awaits further investigation.
Degradation of Cyclins—Degradation of the mitotic cyclins
requires a D-box, which acts as a signal for ubiquitin/protea-
some-mediated proteolysis (9, 10). Despite the similarity in
timing between the destruction cyclin F and the mitotic cyclins,
no obvious D-box is present in cyclin F. Cyclin D and cyclin E
lack the D-box but are also known to be degraded through the
ubiquitin/proteasome-mediated pathway (21, 22, 41). We dem-
onstrated that cyclin F was not ubiquitinated in vivo, and its
destruction was not inhibited by proteasome inhibitors. Fur-
thermore, we have no evidence that cyclin F is ubiquitinated
using an in vitro ubiquitination assay.2
In vivo and in vitro degradation assays suggest that cyclin F
has a short half-life throughout much of the cell cycle. Unfor-
tunately, it is technically difficult to address the important
question of whether the stability of cyclin F changes during G2
phase (when cyclin F normally accumulates) due to the lack of
a good nontoxic G2 cell cycle blocker. In vitro degradation
assays using synchronized cell extracts suggest that there is no
significant change in the stability of cyclin F from S phase to
the subsequent G1 phase.
2
Degradation of F-box Proteins—Cyclin F can associate with
SKP1 (Fig. 7) as well as CUL1 and RBX12 to form a SCF
complex. It is generally believed that proteins containing F-box
are part of the SCF ubiquitin ligase complex that targets dif-
ferent proteins for ubiquitination (20). At this stage, it is un-
clear what proteins are ubiquitinated by SCFcyclin F complexes.
Similar to cyclin F, many F-box proteins oscillates during the
cell cycle. For example, the SKP2 level is high in S phase and
low in M phase (37). Variation of the F-box protein may be an
important way to control the activity of the ubiquitin ligase for
a particular substrate. Whereas it may not be the rule, several
F-box proteins like SKP2 (28), Grr1p, and Cdc4p (26) are
known to be degraded via ubiquitination. Although cyclin F
appears to use a completely different mechanism for degrada-
tion, the down-regulation of cyclin F is nevertheless very ab-
rupt and efficient, in part due to the short half-life of the
protein.
Degradation of PEST-containing Proteins—The presence of
the PEST sequences in cyclin F has been proposed to destabi-
lize the protein (6). Here we show that cyclin F was indeed
more stable when the PEST region was removed. Moreover,
overexpression of the PEST region alone competed for the
degradation of cyclin F, and fusion of the PEST region to cyclin
A rendered the protein less stable. These data suggest that the
PEST region is both necessary and sufficient to destabilize
cyclin F.
Many unstable proteins contain PEST sequences (4), but the
molecular basis of their instability is a mystery. It is unlikely
that a single common mechanism is involved in their degrada-
tion. Interestingly, degradation of cyclin D1 after retinoic acid
treatment of epithelial cells is dependent on the ubiquitin/
proteasome pathway and the PEST region (42). Deletion of the
PEST sequence stabilizes cyclin D1, but it is not clear whether
this affects the ubiquitination. In contrast, the PEST sequences
of the retinoid X receptor  are not required for its ubiquitin/
proteasome-mediated proteolysis (43). Proteasome is not nec-
essarily involved in the degradation of PEST-containing pro-
teins, as for cyclin T1 (44) and cyclin F described here.
Proteolysis of many PEST-containing proteins involves calpain
(16, 17). For IB, two mechanisms of degradation have been
described, one through the ubiquitin/proteasome pathway and
another through calpain. The binding of the PEST sequence of
IB to the calmodulin-like domain -calpain is critical for its
calpain-dependent degradation (16). We believe that the deg-
radation of cyclin F is independent of calpain (Fig. 9), which is
also the case for some other PEST-containing proteins (18, 19).
The PEST sequences of many proteins are phosphorylated.
As exemplified by IB, degradation of IB is dependent on
phosphorylation of its PEST sequence by IK (45, 46). Simi-
larly, phosphorylation of Thr286 in the PEST sequence of cyclin
D1 is also required for its ubiquitin/proteasome-mediated pro-
teolysis (41). Cyclin F typically appeared as multiple bands
(depending on the quality of the gels), suggesting that it was
heavily phosphorylated. These mobility shifts were more
readily observable with the cyclin A-PEST fusion and the
FLAG-PEST. This is not too surprising, since PEST sequences
contain a large number of serine and threonine residues. De-
termination of whether these phosphorylations contribute to
the degradation of cyclin F will require further investigation.
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